The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma

J. H. Donohue, M. Rosenstein, A. E. Chang, M. T. Lotze, R. J. Robb, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Significant serum titers of interleukin 2 (IL 2) can be maintained in mice for 12 h after i.p. injection in a 15% gelatin solution. We have tested the ability of IL 2 administered systemically in this fashion to enhance the therapeutic effect of adoptively transferred specifically sensitized lymphoid cells that were expanded in IL 2. Mice with established local and disseminated FBL-3 lymphoma, induced by intrafootpad injection of 107 cells after 500 rad total body irradiation, were treated with a combination of i.v. injected murine spenocytes and either murine supernatants containing IL 2 or pure human IL 2 in gelatin. Splenocytes from immune mice were resensitized to irradiated tumor in vitro and were expanded for 7 days in lectin-free IL 2 supernatants. Treatment with these murine splenocytes administered with murine IL 2 supernatants prolonged mean survival to 33.6 days compared with mean survival times of 16.9 days (p <0.001) and 23.4 days (p = 0.007) for mice treated with IL 2 alone or splenocytes alone. Human IL 2, purified to homogeneity from the Jurkat cell line, was also capable of improving the therapeutic efficacy of transferred cells in mice. Mean survival was significantly prolonged to 32.1 days when cells and purified human IL 2 were administered, whereas mean survival times of 18.1 days (p +

Original languageEnglish (US)
Pages (from-to)2123-2128
Number of pages6
JournalJournal of Immunology
Volume132
Issue number4
StatePublished - 1984
Externally publishedYes

Fingerprint

Interleukin-2
Lymphoma
Lymphocytes
Gelatin
Injections
Jurkat Cells
Survival
Whole-Body Irradiation
Therapeutic Uses
Lectins
Cell Line
Therapeutics
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Donohue, J. H., Rosenstein, M., Chang, A. E., Lotze, M. T., Robb, R. J., & Rosenberg, S. A. (1984). The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. Journal of Immunology, 132(4), 2123-2128.

The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. / Donohue, J. H.; Rosenstein, M.; Chang, A. E.; Lotze, M. T.; Robb, R. J.; Rosenberg, S. A.

In: Journal of Immunology, Vol. 132, No. 4, 1984, p. 2123-2128.

Research output: Contribution to journalArticle

Donohue, JH, Rosenstein, M, Chang, AE, Lotze, MT, Robb, RJ & Rosenberg, SA 1984, 'The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma', Journal of Immunology, vol. 132, no. 4, pp. 2123-2128.
Donohue, J. H. ; Rosenstein, M. ; Chang, A. E. ; Lotze, M. T. ; Robb, R. J. ; Rosenberg, S. A. / The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. In: Journal of Immunology. 1984 ; Vol. 132, No. 4. pp. 2123-2128.
@article{8751722e20c849f682c09ad49b9019e2,
title = "The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma",
abstract = "Significant serum titers of interleukin 2 (IL 2) can be maintained in mice for 12 h after i.p. injection in a 15{\%} gelatin solution. We have tested the ability of IL 2 administered systemically in this fashion to enhance the therapeutic effect of adoptively transferred specifically sensitized lymphoid cells that were expanded in IL 2. Mice with established local and disseminated FBL-3 lymphoma, induced by intrafootpad injection of 107 cells after 500 rad total body irradiation, were treated with a combination of i.v. injected murine spenocytes and either murine supernatants containing IL 2 or pure human IL 2 in gelatin. Splenocytes from immune mice were resensitized to irradiated tumor in vitro and were expanded for 7 days in lectin-free IL 2 supernatants. Treatment with these murine splenocytes administered with murine IL 2 supernatants prolonged mean survival to 33.6 days compared with mean survival times of 16.9 days (p <0.001) and 23.4 days (p = 0.007) for mice treated with IL 2 alone or splenocytes alone. Human IL 2, purified to homogeneity from the Jurkat cell line, was also capable of improving the therapeutic efficacy of transferred cells in mice. Mean survival was significantly prolonged to 32.1 days when cells and purified human IL 2 were administered, whereas mean survival times of 18.1 days (p +",
author = "Donohue, {J. H.} and M. Rosenstein and Chang, {A. E.} and Lotze, {M. T.} and Robb, {R. J.} and Rosenberg, {S. A.}",
year = "1984",
language = "English (US)",
volume = "132",
pages = "2123--2128",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma

AU - Donohue, J. H.

AU - Rosenstein, M.

AU - Chang, A. E.

AU - Lotze, M. T.

AU - Robb, R. J.

AU - Rosenberg, S. A.

PY - 1984

Y1 - 1984

N2 - Significant serum titers of interleukin 2 (IL 2) can be maintained in mice for 12 h after i.p. injection in a 15% gelatin solution. We have tested the ability of IL 2 administered systemically in this fashion to enhance the therapeutic effect of adoptively transferred specifically sensitized lymphoid cells that were expanded in IL 2. Mice with established local and disseminated FBL-3 lymphoma, induced by intrafootpad injection of 107 cells after 500 rad total body irradiation, were treated with a combination of i.v. injected murine spenocytes and either murine supernatants containing IL 2 or pure human IL 2 in gelatin. Splenocytes from immune mice were resensitized to irradiated tumor in vitro and were expanded for 7 days in lectin-free IL 2 supernatants. Treatment with these murine splenocytes administered with murine IL 2 supernatants prolonged mean survival to 33.6 days compared with mean survival times of 16.9 days (p <0.001) and 23.4 days (p = 0.007) for mice treated with IL 2 alone or splenocytes alone. Human IL 2, purified to homogeneity from the Jurkat cell line, was also capable of improving the therapeutic efficacy of transferred cells in mice. Mean survival was significantly prolonged to 32.1 days when cells and purified human IL 2 were administered, whereas mean survival times of 18.1 days (p +

AB - Significant serum titers of interleukin 2 (IL 2) can be maintained in mice for 12 h after i.p. injection in a 15% gelatin solution. We have tested the ability of IL 2 administered systemically in this fashion to enhance the therapeutic effect of adoptively transferred specifically sensitized lymphoid cells that were expanded in IL 2. Mice with established local and disseminated FBL-3 lymphoma, induced by intrafootpad injection of 107 cells after 500 rad total body irradiation, were treated with a combination of i.v. injected murine spenocytes and either murine supernatants containing IL 2 or pure human IL 2 in gelatin. Splenocytes from immune mice were resensitized to irradiated tumor in vitro and were expanded for 7 days in lectin-free IL 2 supernatants. Treatment with these murine splenocytes administered with murine IL 2 supernatants prolonged mean survival to 33.6 days compared with mean survival times of 16.9 days (p <0.001) and 23.4 days (p = 0.007) for mice treated with IL 2 alone or splenocytes alone. Human IL 2, purified to homogeneity from the Jurkat cell line, was also capable of improving the therapeutic efficacy of transferred cells in mice. Mean survival was significantly prolonged to 32.1 days when cells and purified human IL 2 were administered, whereas mean survival times of 18.1 days (p +

UR - http://www.scopus.com/inward/record.url?scp=0021324518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021324518&partnerID=8YFLogxK

M3 - Article

C2 - 6607956

AN - SCOPUS:0021324518

VL - 132

SP - 2123

EP - 2128

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -